Tsen‐Fang Tsai

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Diamant Thaçi, Andrew Blauvelt, Kristian Reich et al. · Journal of the American Academy of Dermatology · 2015 · 537 citations · Full text

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 390 citations · Full text

Rheumatoid Disorder, Rheumatology, Spirit-p2 Phase 3 +12

Tumor-Associated Macrophage-Induced Invasion and Angiogenesis of Human Basal Cell Carcinoma Cells by Cyclooxygenase-2 Induction

Jeng‐Wei Tjiu, Jau‐Shiuh Chen, Chia‐Tung Shun et al. · Journal of Investigative Dermatology · 2008 · 346 citations · Full text

Tumor-associated Macrophage-induced Invasion, Tumor Biology, Cyclooxygenase-2 Induction +9

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp> trial

Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin et al. · British Journal of Dermatology · 2017 · 336 citations · Full text